title: Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of hypofractionated stereotactic body radiotherapy in patients with Stage I/II non-small-cell lung cancer.
  
  
  METHODS
  Forty-three patients with inoperable Stage I/II non-small-cell lung cancer underwent treatment prospectively using the stereotactic gamma-ray whole-body therapeutic system (body gamma-knife radiosurgery) with 30 rotary conical-surface Co(60) sources focused on the target volume. Low-speed computed tomography simulation was conducted, which was followed by three-dimensional conformal radiotherapy planning. A total dose of 50 Gy was delivered at 5 Gy/fraction to the 50% isodose line covering the planning target volume, whereas a total dose of 70 Gy was delivered at 7 Gy/fraction to the gross target volume. The median follow-up duration was 27 months.
  
  
  RESULTS
  Three to 6 months after treatment, the complete response rate for body-gamma knife radiosurgery was 63%, and the overall response rate was 95%. The 1-year, 2-year, and 3-year local control rates were all 95% in all patients. The 1-year, 2-year, and 3-year overall survival rates were 100%, 91%, and 91%, respectively, in patients with Stage I disease and 73%, 64%, and 64%, respectively, in those with Stage II disease. Only 2.3% (1/43) of the patients had Grade 3 pneumonitis.
  
  
  CONCLUSIONS
  Our highly focused stereotactic body radiotherapy method resulted in promising local control and survival with minimal toxicity.
authors.affiliation: Department of Radiation Oncology, Air Force General Hospital, Beijing, People's Republic of China. xiatingyi1959@21cn.com
authors.forename: Tingyi
authors.initials: T
authors.lastname: Xia
authors.forename: Hongqi
authors.initials: H
authors.lastname: Li
authors.forename: Qingxuan
authors.initials: Q
authors.lastname: Sun
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Wang
authors.forename: Naibin
authors.initials: N
authors.lastname: Fan
authors.forename: Yong
authors.initials: Y
authors.lastname: Yu
authors.forename: Ping
authors.initials: P
authors.lastname: Li
authors.forename: Joe Y
authors.initials: JY
authors.lastname: Chang
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D017564:Radiation Pneumonitis / Q000209:etiology; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D011879:Radiotherapy Dosage